Our History

Prestige Biopharma

Major Achievements​

2023

07 

Selected as a member of the ‘CANCER X’ project.

03

Receives FDA Fast Track Designation for PBP1510 in the Treatment of Pancreatic Cancer

02

Final Analysis of Phase 3 Clinical Trial of HD201 published in ‘BMC Cancer’​

01

Obtains a Patent in Korea for Its Novel Antibody ‘PBP1710’ for Solid Cancer Treatment​

2022

11

Obtains PBP1510 Patent in Indonesia​

11

Prestige Biopharma Korea Receives 2022 Foreign Company Day Award​

10

Publish New Findings on PAUF-induced Cancer Cell Migration and Its Pathway

08​

Obtains PBP1510 Patent in Singapore​

06​

US FDA Approves IND for Phase 1/2a trial of First-in-Class Pancreatic Cancer Treatment, PBP1510​​

03​

Winner for Bioprocessing Excellence in SEA​​​

03​

Establishment of Advanced Research Center (ARC) in Boston, USA​​

2021

02

IPO on the Korea Composite Stock Price Index (KOSPI)​

2020

11

EU EMA ODD approval for pancreatic cancer drug (PBP1510)​

07

Korea MFDS ODD approval for pancreatic cancer drug (PBP1510)​

06

US FDA ODD approval for pancreatic cancer drug (PBP1510)​

2015

07

Establishment of Prestige Biopharma Limited​

Prestige Biopharma, founded in Singapore in 2015, is primarily dedicated to the research and development of biosimilar products. In February 2021, the company went public on the South Korean stock market.

Prestige Biopharma continues its research and development of key biosimilar pipeline products, with its R&D center and headquarters based in Biopolis, Singapore. Additionally, from 2022, the company has expanded its research efforts by establishing Innovative Discovery Center (IDC) in Busan, South Korea, to prepare for the future of novel drugs. Through these efforts, Prestige Biopharma contributes to developing innovative products in the biopharmaceutical field, providing more effective and safer pharmaceuticals.

In addition, Prestige Biologics, a company engaged in biopharmaceutical production services, underwent vertical integration with Prestige Biopharma in 2022, completing the ecosystem of the biopharmaceutical value chain. As a result, Prestige Biopharma Group has achieved a comprehensive and integrated biopharmaceutical ecosystem, encompassing research, development, production, and marketing of biopharmaceutical products. Prestige Biopharma Group consists of three main companies: Prestige Biopharma, which focuses on bio-pharmaceutical development; Prestige Biologics, responsible for biomanufacturing service; and Prestige Biopharma IDC, dedicated to researching novel antibody drugs, vaccines, diagnostics, and various new modalities of therapeutics.